Document is current
Any future updates will be listed below
-
Authors
Nezu, Mari
Ueda, Shinichiro
Uchida, Kazutaka
Sakakibara, Fumihiro
Kinjo, Norito
Arai, Hideki
Morimoto, Takeshi https://orcid.org/0000-0002-6844-739X
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
Japan Society for the Promotion of Science (JP21H03176)
- License Information
-
More Information
Article History
Received: 22 May 2022
Accepted: 20 October 2022
First Online: 4 November 2022
Declarations
:
: Shinichiro Ueda reports receiving a research grant from Bristol-Myers Squibb, Chugai, Kowa, MSD, Pfizer, and Takeda, lecturer’s fees from Boehringer Ingelheim, MSD, and Taiho, and manuscript fees from Kowa. He served on an advisory board for Otsuka. Kazutaka Uchida reports lecturer’s fees from Daiichi Sankyo. Takeshi Morimoto reports lecturer's fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Toray, and Tsumura; manuscript fees from Bristol-Myers Squibb and Kowa; advisory board for Novartis and Teijin. Mari Nezu, Fumihiro Sakakibara, Norito Kinjo, and Hideki Arai have no disclosures to report.
: The institutional review boards of University of the Ryukyus (No. 597) and all 71 participating centers approved the study protocol (Online Resource Table 1). The institutional review boards waived the need for written informed consent and approved the study in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan.
